AIM VACCINE (06660) announced that its wholly-owned subsidiary, Aim Honor (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the on-site inspection for the registration of its globally first self-developed serum-free next-generation rabies vaccine. Based on technical review requirements outlined by the Center for Drug Evaluation of the National Medical Products Administration, the on-site inspection for the vaccine (Acceptance No.: CXSS2500044) has been completed. Results from the unblinded Phase III clinical study demonstrate that the serum-free next-generation rabies vaccine exhibits excellent safety, immunogenicity, and lasting immunity, meeting all pre-established clinical trial evaluation criteria. The subsidiary has already obtained the necessary production license for the vaccine. Currently, there are no serum-free rabies vaccines approved for market use globally. Upon approval, AIM VACCINE's product is expected to address this market gap, marking a significant technological breakthrough and reinforcing the group's leading position in the rabies vaccine sector. Unlike traditional Vero cell-based and human diploid cell rabies vaccines, this serum-free next-generation vaccine represents a major upgrade. The absence of animal serum components significantly enhances safety by reducing the risk of allergic reactions and adverse effects associated with serum residues. China is the world's largest rabies vaccine market, projected to reach RMB 14.8 billion by 2030, driven by product innovation and increased vaccination rates. According to national guidelines, rabies vaccination clinics are required to stock at least two different types of rabies vaccines. AIM VACCINE's advanced product is well-positioned to become a preferred choice for vaccination providers. As the world's second-largest rabies vaccine supplier, the group is committed to leading technological advancements in the field. It has established a serum-free next-generation rabies vaccine production facility meeting international standards and completed validation for commercial-scale manufacturing, ensuring rapid market deployment upon regulatory approval. The future launch of this vaccine is anticipated to significantly boost the group's financial performance.